Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C

Liver International

Volumn 29, Issue 9, 2009, Pages 1403-1412

  Younossi, Zobair M ^a,b,c   Afendy, Arian ^a   Stepanova, Maria ^a   Hossain, Noreen ^a   Younossi, Issah ^a   Ankrah, Kathy ^a   Gramlich, Terry ^d   Baranova, Ancha ^a,b,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Chronic hepatitis C infection; fibrosis; Gene expression; Genotype 3; Steatosis

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN KINASE R; RNA; SMAD3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOUSEKEEPING GENE; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; CLASSIFICATION; FATTY LIVER; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED; VIROLOGY;

ADULT; FATTY LIVER; FEMALE; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 70449707799     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02060.x     Document Type: Article

References (37)

1. Ong JP, Younossi Z.M. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16.
2. Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005; 41: 1151-9.
3. Rafiq N, Younossi Z.M. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2008; 2: 207-15.
4. Cheung O, Sanyal A.J. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis 2008; 12: 573-85, viii-ix.
5. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
6. Pazienza V, Cl'ement S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-71.
7. Roingeard P, Hourioux C. Hepatitis C virus core protein, lipid droplets and steatosis. J Viral Hepat 2008; 15: 157-64.
8. McPherson S, Jonsson JR, Barrie HD, et al. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol 2008; 49: 1046-54.
9. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-9.
10. Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008; 118: 683-94.
11. Bondini S, Younossi Z.M. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 2006; 52: 135-43.
12. Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2008; 15: 129-36.
13. Bondini S, Kallman J, Wheeler A, Prakash S, Gramlich T, Jondle D, Younossi Z.M. The Impact of Non-Alcoholic Fatty Liver Disease on Chronic Hepatitis B. Liver Int 2007; 27: 607-11.
14. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. Clin Gastroenterol 2004; 38: 705-9.
15. Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007; 46: 380-7.
16. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.
17. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44: 1648-55.
18. Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6: 22-9.
19. Conjeevaram HS, Kleiner DE, et al. Virahep-C Study Group. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-7.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
21. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-5.
22. Younossi ZM, Baranova A, Afendy A, et al. Gene expression biomarkers predicting sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Hepatology 2009; 49: 763-74.
23. Garcia EP, Dowding LA, Stanton LW, Slepnev V.I. Scalable transcriptional analysis routine - multiplexed quantitative real-time polymerase chain reaction platform for gene expression analysis and molecular diagnostics. J Mol Diagn 2005; 7: 444-54.
24. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology 1993; 11: 1026-30.
25. Livak KJ, Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
26. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proc. Fourteenth Int Joint Conf Artif Intellig 1995; 2: 1137-43.
27. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123: 2082-99.
28. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005; 25: 31-58.
29. Wacher C, Müller M, Hofer MJ, et al. Coordinated regulation and widespread cellular expression of interferonstimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol 2007; 81: 860-71.
30. Arif A, Levine RA, Sanderson SO, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003; 48: 1425-30.
31. Masarone M, La Mura V, Bruno S, et al. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCVrelated chronic liver disease. J Viral Hepat 2007; 14: 714-20.
32. Nieminen U, Arkkila PE, Kärkkäinen P, Färkkilä M.A. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. Liver Int 2009; 29: 153-8.
33. Missiha SB, Ostrowski M, Heathcote E.J. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-714.
34. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005; 129: 2064-75.
35. Rigopoulou EI, Abbott WG, Haigh P, Naoumov N.V. Blocking of interleukin-10 receptor - a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin Immunol 2005; 117: 57-64.
36. Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 2002; 294: 94-105.
37. Treeck O, Kindzorra I, Pauser K, Treeck L, Ortmann O. Expression of icb-1 gene is interferon-gamma inducible in breast and ovarian cancer cell lines and affects the IFN gamma-response of SK-OV-3 ovarian cancer cells. Cytokine 2005; 32: 137-42.